Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $300,000
- Closes
- Nov 10, 2026 (in 60 days)
Similar opportunities open now
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 60 daysUp to $150K
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 2028
- Metastasis Research Network (U54 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 14 daysUp to $1.3M
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses in 38 daysUp to $600K
Classification and identifiers
- Solicitation number
- RFA-CA-27-002
- Assistance listing (CFDA)
- 93.394
Amount
$300,000
Who can apply
State government agencies, Public colleges and universities, and Nonprofits, including small and volunteer-run organizations can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologi...